Skip Navigation

European Heart Journal 2002 23(20):1604-1608; doi:10.1053/euhj.2002.3312
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Angiogenesis in myocardial infarction. An acute or chronic process?

N.A.Y. Chung, C. Lydakis, F. Belgore, A.D. Blann and G.Y.H. Lipf1

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K.

revised May 12, 2002; accepted May 22, 2002

Abstract

Background In the acute phase of myocardial infarction (acute MI) marked endothelial damage occurs within the first 24h following thrombolysis with streptokinase. We investigated whether this is associated with a change in levels of vascular endothelial growth factor (VEGF, possibly marking angiogenesis) in the first 24h post thrombolysis compared to chronic MI patients (defined as MI>3 months previously).

Methods We recruited 15 patients (nine male, mean age 59±SD 10 years) with first-presentation acute MI, who were given 1·5 million U streptokinase over 1h and aspirin 300mg orally as standard treatment. Plasma samples were taken prior to the start of thrombolysis, followed every 15min for 1h, at 3h and finally at 24h post-thrombolysis. Baseline levels of measured indices in the acute MI patients were compared to two control groups: (i) 26 chronic MI patients (18 male, mean age 59·9±7·0 years); and (ii) 26 apparently healthy controls (17 male, mean age 59·6±14·1 years). Plasma VEGF and the soluble form of its receptor Flt-1 (sFlt-1) were measured by ELISA.

Results Plasma levels of VEGF were significantly higher in patients with a history of chronic MI compared to patients with acute MI (P=0·007) and healthy controls (P=0·002) with similar levels between acute MI patients and healthy controls (P=0·755). Levels of sFlt-1 in the acute (P=0·013) and chronic (P<0·001) MI groups were lower compared to healthy controls. In the first 24h post-thrombolysis in the acute MI group, levels of sFlt-1 changed significantly (P=0·039), but there was no change in levels of VEGF (P=0·207).

Conclusion In the first 24h of acute MI, significant changes in levels of VEGF receptor sFlt-1, but not VEGF, are seen. Plasma VEGF and sFlt-1 levels are markedly changed in chronic MI patients, suggesting that the activation of angiogenesis in MI patients may be a delayed response. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Angiogenesis, vascular endothelial growth (VEGF), soluble Flt-1, myocardial infarction (MI)

f1 Correspondence: Professor G. Y. H. Lip, Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
Q. Guo, J. J. Carrero, X. Yu, P. Barany, A. R. Qureshi, M. Eriksson, B. Anderstam, M. Chmielewski, O. Heimburger, P. Stenvinkel, et al.
Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3468 - 3473.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Kodama, Y. Kitta, T. Nakamura, H. Takano, K. Umetani, D. Fujioka, Y. Saito, K.-i. Kawabata, J.-e. Obata, A. Mende, et al.
Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction
J. Am. Coll. Cardiol., July 4, 2006; 48(1): 43 - 50.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. W. Lee, G. Y.H. Lip, and A. D. Blann
Plasma Angiopoietin-1, Angiopoietin-2, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor Levels in Acute Coronary Syndromes
Circulation, October 19, 2004; 110(16): 2355 - 2360.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. S. Werner, E. Jandt, A. Krack, G. Schwarz, O. Mutschke, F. Kuethe, M. Ferrari, and H. R. Figulla
Growth Factors in the Collateral Circulation of Chronic Total Coronary Occlusions: Relation to Duration of Occlusion and Collateral Function
Circulation, October 5, 2004; 110(14): 1940 - 1945.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.